Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 15/20 | 0.70 |
| ▸ | NPC1 | O15118 | 11/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27578747 | 0.87 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL4113524 | 0.84 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2KMT2AL3MBTL1 | |
| SCHEMBL27578807 | 0.83 | RAB9A (0.74) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL4112512 | 0.83 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL16383911 | 0.82 | RAB9A (1.00) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL27581139 | 0.82 | RAB9A (0.73) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL4112875 | 0.81 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL23977709 | 0.80 | RAB9A (0.70) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL4113855 | 0.79 | RAB9A (0.79) | RAB9ANPC1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL27568918 | 0.79 | RAB9A (0.68) | RAB9ANPC1SMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | NEUROGEN CORPORATION | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239841-A1 | Diaryl Ureas as CB1 Antagonists | CNR1, CNR2, OPRL1 | RAB9A 815/4885NPC1 927/4885SMN1; SMN2 4056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.